10-Feb-15 Encouraged by a relaxation of ownership rules in 2014 and a rapidly ageing population, PE firms and industry players are investing in China’s hospitals, pharmaceutical companies and device makers. The prospect of 223 million people aged 65+ by 2030 is enticing, despite risks such as rising valuations and a dearth of doctors. [image: Reuters]

31-Jan-15 Japan's Chugai Pharmaceutical will invest $476 million over the next seven years to expand its research institute in Singapore. The investment will make its centre at Biopolis one of the biggest pharmaceutical research and development operations in Singapore. It will also boost its "local employee base and antibody research and development pipeline", the company said. [image: Reuters]

26-Jan-15 Many players in the healthcare industry continue to rely on a distribution model that hasn’t changed in decades. But new market pressures are forcing a reconsideration of the status quo. Direct-to-market distribution via 3PL providers is one cost-effective answer, says DHL, especially in emerging markets. [image: Supply Chain Matter / DHL]

25-Jan-15The Chinese pharmaceutical sector saw lower growth in 2014 due to a host of challenges including slowing overall economic growth, regulatory shakeups, cost containment measures and price cuts, as well as healthcare reform turbulence. However, the market is still estimated to have grown 13% in 2014, to reach USD200 billion. [image: My Jungle Blog]

For more about China's healthcare sector, request our free 20-page whitepaper: China Healthcare Market Opportunities

09-Jan-15 The China Food and Drug Administration (CFDA) plans to allow online sales of prescription drugs soon. If approved, the policy could seed a market worth more than USD160 billion as sales shift from hospitals to online platforms such as Alibaba and JD.com. [image: Reuters/Stringer]